Mosaic ImmunoEngineering Inc. has agreed to acquire the rights to Oncotelic Therapeutics Inc.’s clinical-stage necroptosis cancer therapies.   Oncotelic’s necroptosis therapeutics work by disrupting tumor blood flow resulting in immunogenic tumor cell death through “death receptor” activation which can result in a robust anti-cancer immune response. In addition to the clinical stage assets, Mosaic will have access to Oncotelic’s proprietary Artificial Intelligence (AI) technologies for identif...